



# Antibiotic Susceptibility of *Klebsiella pneumoniae* Isolates from Hospitalized Patients in Three Referral Medical Centers in Isfahan, Iran

Sayed Nassereddin Mostafavi Esfahani <sup>1,2,3,\*</sup>, Soodabeh Rostami<sup>4</sup>, Abtin Astaraki<sup>2</sup>

<sup>1</sup> Department of Pediatric Infectious Disease, Isfahan University of Medical Sciences, Isfahan, Iran

<sup>2</sup> Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

<sup>3</sup> Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran

<sup>4</sup> Nosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

\*Corresponding author: Department of Pediatric Infectious Disease, Isfahan University of Medical Sciences, Isfahan, Iran. Email: n\_mostafavy@med.mui.ac.ir

Received 2023 August 26; Revised 2023 December 24; Accepted 2024 April 7.

## Abstract

**Background:** *Klebsiella pneumoniae* (*K. pneumoniae*) is a major cause of nosocomial and community-acquired infections (CAIs). Understanding the antibiotic susceptibility of this bacterium is essential for selecting the most effective antibiotic for associated infections. **Objectives:** We investigated the sensitivity of *K. pneumoniae* (*KP*) isolates obtained from inpatients in Isfahan, Iran. **Methods:** Organism identification and antibiotic susceptibility testing were conducted using standard tests. Stratification was performed based on extended spectrum beta-lactamase (ESBL) production and the source of infection acquisition (community versus hospital). **Results:** A total of 437 *KP* isolates were investigated, of which 5.5% were pan drug resistant (PDR), 56.8% were extensively drug resistant (XDR), and 18% were ESBL producers. The isolates were most susceptible to colistin (100%), aminoglycosides (62.8%), and carbapenems (55%). Nosocomial isolates showed lower sensitivity to most of the examined antibiotics. **Conclusions:** The high prevalence of PDR and XDR *KP* strains in hospitalized patients is a major problem in the studied area.

**Keywords:** *Klebsiella Pneumoniae*, Microbial Sensitivity, Tests, Drug Resistance, Iran

## 1. Background

*Klebsiella pneumoniae* (*K. pneumoniae*) is a Gram-negative bacillus of the Enterobacteriaceae family, which is a major cause of many infections, including urinary tract infection, sepsis, bacteremia, meningitis, and skin and soft tissue infections (1).

The bacterium is the most common cause of hospital-acquired infections and a primary etiology of community-acquired infections (CAIs) (1).

Unfortunately, in recent years, with the global emergence of antibiotic resistance among pathogens, the bacterium's susceptibility to current antibiotics decreased dramatically. Now the strain is the main cause of multi-drug resistance (MDR), extensive drug resistance (XDR), and even pan drug resistance (PDR) infections, particularly in hospital-acquired infections (2).

One of the most important mechanisms of resistance of the bacterium to antibiotics is the production of enzymes nominated as extended spectrum beta-lactamase (ESBL). These proteins hydrolyze and inactivate a wide range of antibiotics, including all penicillins and first, second, and third-generation cephalosporins (2).

During the past years, the last choice of antibiotic for treating ESBL-producing Enterobacteriaceae was carbapenems. Unfortunately, during recent years, the prevalence of carbapenemase-producing *K. pneumoniae* (*KP*) increased dramatically, and the treatment of associated infections became challenging (1, 2).

Multi-drug resistance *K. pneumoniae* strains have been reported from many regions globally, but their prevalence varies in different countries. The prevalence of ESBL-producing *K. pneumoniae* strains was 36.8% in Philippines, Singapore (3), 5.1% in Japan (4), Tunisia (5), 33.9% in Turkey (6), and 59.2% in Iran (7). In addition, the

prevalence of carbapenem-resistant *K. pneumonia* strains in the United States, Italy, and China was 9.7%, 17.4%, and 7.1%, respectively (8-10).

To choose the best antibiotic for the empiric treatment of infections caused by this bacteria, it is necessary to know the antibiotic susceptibility of the bacterium in each geographic area (11).

Previous investigations into the antibiotic susceptibility of *K. pneumonia* in Iran have had some limitations, such as the inclusion of contaminant isolates in the analysis (12-16), small sample sizes (12-16), failure to differentiate nosocomial and community strains (12-15), and inclusion of only ESBL-producing isolates, limiting their utility in the empiric treatment of *K. pneumonia* infections in the region (12-16).

## 2. Objectives

Therefore, we decided to investigate and report the prevalence and antibiotic sensitivity pattern of *K. pneumonia* isolates according to the source of the infection (hospital versus community) and production of ESBL (producer versus non-producer) in inpatients from three referral hospitals in Isfahan, Central Iran.

## 3. Methods

### 3.1. Study Design

This study is part of a comprehensive project on antibacterial resistance in Isfahan, Iran, conducted from March 2016 to March 2018, named "Isfahan Antimicrobial Resistance Surveillance-1" (IAS-1). Isfahan antimicrobial resistance surveillance-1 aimed to determine the antibiotic susceptibility patterns of common bacteria isolated from inpatients with established infections in three large medical centers in Isfahan, Iran: Alzahra, Dr. Shariati, and Dr. Gharazi Hospitals, which collectively have more than 1,300 beds. Their laboratories are approved for quality by the Iranian Ministry of Health for microbiological tests and collaborate with the World Health Organization in the Global Antimicrobial Resistance Surveillance System (17).

In addition to registering the antibiotic susceptibility of clinical isolates, this program aimed to determine contaminated samples and identify the source of infection, whether from the hospital or the community, through trained nurses and physicians. If the *K. pneumonia* species was isolated from a site with no clinical or para-clinical manifestations of infection, it was considered a contaminant and excluded from the

study. Samples were collected after 48 hours of hospitalization, and all samples obtained from internal devices were categorized as nosocomial isolates, while others were classified as community-acquired organisms (17).

This study aimed to report the antibiotic resistance pattern of *KP* isolates in the IAS-1 program.

### 3.2. Identification of Organism

Identification of *KP* species and determination of the susceptibility pattern of the isolates were conducted using standard tests as guided by the Clinical Laboratory Standards Institute (18). The susceptibility of the samples was examined against the following classes of antibiotics: Aminoglycosides (Gentamicin or Amikacin), third-generation cephalosporins (cefotaxime or ceftriaxone), antipseudomonal third-generation cephalosporin (ceftazidime), fourth-generation cephalosporin (cefepime), fluoroquinolones (ciprofloxacin), folate inhibitors (trimethoprim-sulfamethoxazole), and carbapenems (imipenem or meropenem). Dehydrated discs from MAST, Merseyside, UK, and MIC strips from Liofilchem, Italy, were used in the study.

Isolates that were resistant to at least three classes of the examined antibiotics were classified as MDR. Those resistant to more than three tested antibiotic classes were considered possibly XDR, and those resistant to all examined antibiotic classes were deemed possibly PDR (19).

### 3.3. Statistical Analysis

The results of antibiotic susceptibility, ESBL production, and source of infection acquisition (hospital versus community) of *KP*, as well as the diagnosis and age group of the patients (< 20 years versus > 20 years), were recorded in WHONET software version 5.6 in each participating laboratory. Analysis was conducted using SPSS software version 18. To compare antibiotic susceptibility across different groups, chi-square or Fisher exact tests were employed. A P-value of less than 0.05 was considered statistically significant. The study was assessed and approved by the Institutional Review Board of Isfahan University of Medical Sciences (approval number: [IR.MUI.MED.REC.1399.502](https://doi.org/10.30472/IR.MUI.MED.REC.1399.502)).

## 4. Results

A total of 563 separate *KP* strains were isolated, of which 126 (22.4%) samples were considered

**Table 1.** Sensitivity Profile of *Klebsiella pneumoniae* in Accordance to Source of the Infection in Patients Admitted in Three Referral Hospitals in Isfahan, Iran

Antibiotic class	Sensitivity of the Isolates: Number of Patients (Percent)				
	Community Acquired	Healthcare Associated	P-Value	Total <sup>a</sup> n/N (%)	
<b>Carbapenems</b>		200.252 (79.3)	67.233 (28.7)	< 0.001	267.485 (55.0)
Antipseudomonas third generation cephalosporin		81.195 (41.5)	31.221 (14)	< 0.001	112.416 (26.9)
<b>Third generation cephalosporins</b>		52.126 (41.2)	14.63 (22.2)	0.010	66.189 (34.9)
<b>Fourth generation cephalosporin</b>		89.192 (46.4)	29.217 (13.4)	< 0.001	118.409 (28.8)
<b>Aminoglycosides</b>		198.257 (77.0)	119.247 (48.1)	< 0.001	317.50 (62.8)
<b>Folate inhibitors</b>		47.129 (36.4)	38.123 (30.9)	0.352	85.252 (33.7)
<b>Fluoroquinolones</b>		84.185 (45.4)	21.161 (13)	< 0.001	105.346 (30.3)
<b>Colistin</b>		9.9 (100)	23.23 (100)	-	32.32 (100)
<b>Multi-drug resistance (MDR)</b>		82.207 (39.6)	172.230 (74.8)	< 0.001	254.437 (58.1)
<b>Possible extensive drug resistance (XDR)</b>		76.207 (36.7)	172.230 (74.8)	< 0.001	248.437 (56.8)
<b>Possible pan drug resistance (PDR)</b>		3.20 (1.4)	23.230 (10)	< 0.001	26.437 (5.5)

<sup>a</sup> n/N (%); number of sensitive isolates/ total number of examined isolates (percent).

contamination. Of the 437 patients with documented *KP* infection, 258 (59%) were male, 57 (13%) were under 20 years old, and 207 (47.4%) acquired the infection from the community.

Most strains were isolated from patients with bloodstream infections (143; 32.7%), followed by urinary tract infections (141; 32.3%), skin and soft tissue infections (78; 17.8%), and other infections (75; 17.2%). Extended spectrum beta-lactamase production was reported in 79 (18%) of the isolates, including 57 (27.5%) from CAIs and 22 (9.6%) from healthcare-associated infections (HAIs).

No antibiotic showed a high antibacterial effect on the isolated *KP* strains. The highest susceptibility of the isolates was to aminoglycosides (62.8%) and carbapenems (55%). Lower sensitivity was observed to third-generation cephalosporins (34.9%), folate inhibitors (33.7%), fluoroquinolones (30.3%), fourth-generation cephalosporins (28.8%), and antipseudomonal third-generation cephalosporins (26.9%). The sensitivity of the organism to all examined antibiotics, except folate inhibitors, was significantly higher in CAIs than in infections acquired from healthcare settings ((Table-1).

Extended spectrum beta-lactamase-producing *KP* strains demonstrated high susceptibility to carbapenems (92.6%), intermediate sensitivity to aminoglycosides (63.1%), and low susceptibility to fluoroquinolones (28.7%), folate inhibitors (15.8%), and both fourth and third-generation cephalosporins (less than 12.9%) ((Table-2). In contrast, while community-acquired strains showed higher susceptibility to aminoglycosides compared to nosocomial isolates among ESBL producers, the sensitivity of nosocomial

strains to folate inhibitors was significantly higher than that of community-acquired isolates ((Table-2).

## 5. Discussion

*Klebsiella pneumoniae* is one of the most common causes of infections among hospitalized patients, especially those with HAIs, and it exhibits a high level of resistance to various antibiotics in earlier studies (1, 2). Evaluating resistance to various antibiotics in different geographical areas is crucial for choosing the appropriate antibiotic for patients at high risk of *KP*-induced infection (13). Previous studies on the antibiotic susceptibility of this bacterium in Iran did not recognize and eliminate contaminant isolates from the final analysis (12-16). Moreover, antibiotic susceptibility of *KP* strains has not been reported separately for community-acquired and hospital-acquired isolates (12-15). Therefore, these studies do not provide complete information for determining the best antibiotics for treating *KP*-induced infections in different clinical settings.

The present study investigated the susceptibility of 437 true *KP* clinical isolates to eight classes of antibiotics and showed that a high percentage of the isolates are either PDR (5.5%) or XDR (56.8%). Similar to our investigation, previous studies in Ethiopia and Italy reported high rates of PDR and XDR isolates (20, 21), indicating that resistance of this bacterium to different classes of antibiotics is a global issue, necessitating worldwide efforts to combat it.

The present study revealed that colistin was the only antibiotic with high in vitro activity against *KP* isolates. Unfortunately, this drug does not exhibit much in vivo

**Table 2.** Sensitivity Profile of Extended Spectrum Beta-Lactamase Producer *Klebsiella pneumoniae* Strains in Accordance to Source of the Infection in Patients Admitted in Three Referral Hospitals in Isfahan, Iran

Antibiotic	Sensitivity of Extended Spectrum Beta-Lactamase Producer <i>K. Pneumoniae</i> Strains: Number of Patients (Percent)			
	Community Acquired <sup>a</sup> n/N (%)	Healthcare Associated <sup>a</sup> n/N (%)	P-Value	Total <sup>a</sup> n/N (%)
Carbapenems	66.72 (91.6)	22.23 (95.6)	1	88.95 (92.6)
Antipseudomonas third generation cephalosporins	1.57 (1.8)	0.22 (0)	1	1.79 (1.3)
Third generation cephalosporins	0.42 (0.0)	0.9 (0.0)	-	0.51 (0)
Fourth generation cephalosporins	8.57 (14)	2.20 (10)	1	10.77 (12.9)
Aminoglycosides	52.72 (72.2)	8.23 (34.7)	0.001	60.95 (63.1)
Folate inhibitors	3.42 (7.1)	7.21 (33.3)	0.012	10.63 (15.8)
Fluoroquinolones	16.55 (29.1)	3.11 (27.3)	1	19.66 (28.7)
Colistin	4.4 (100)	2.2 (100)	-	6.6 (100)

<sup>a</sup> n/N (%); number of sensitive isolates/ total number of examined isolates (percent).

effectiveness for the treatment of bacterial infections. Therefore, combining colistin with other antibiotics could be more practical in the initial treatment of infections likely to be caused by this microorganism (22). Similar to our findings, studies conducted in France, England, and Italy reported high susceptibility of *KP* strains to colistin (23-25). On the other hand, investigations in Saudi Arabia and Tehran, Iran, showed low susceptibility of *KP* isolates to this drug (40.7% and 45.0% respectively) (14, 26). The explanation for this discrepancy could be related to the site of specimen selection and differences in antibiotic prescription practices across different geographical areas.

The antibiotic susceptibility of *KP* strains in the present study showed intermediate susceptibility to aminoglycosides (62.8%) and carbapenems (55%). Susceptibility to these classes of antibiotics was significantly higher in CAIs than in HAIs (77% in CAIs versus 48.1% in HAIs for aminoglycosides; and 79.3% in CAIs versus 28.7% in HAIs for carbapenems). This difference indicates the need for combining these antibiotics with colistin for treating severe nosocomial infections caused by this bacterium. A high level of resistance among nosocomial *KP* strains to aminoglycosides (51.9%) and carbapenems (71.3%) suggests a high rate of treatment failure in infected patients. This alarming finding underscores the urgent need for strategies to prevent resistance among nosocomial bacteria through rational antibiotic prescription in both hospital and community settings.

Similar susceptibility of *KP* isolates to aminoglycosides has been previously reported from Saudi Arabia (55.8%), India (58.5%), and Iran (60.4%) (13, 26, 27). Additionally, the susceptibility of *KP* strains to carbapenems in our study was similar to research

conducted in Saudi Arabia in 2020 (57.75%) (26). Conversely, higher susceptibility to carbapenems has been reported from France (100%) (23), Kenya (77.7%) (28), India (68%) (29), and Iran (86.3%) (13). The higher resistance of *KP* strains in our study compared to other regions may be due to geographic variations in resistant *KP* strains.

The present study revealed that *KP* strains exhibited low susceptibility to third- and fourth-generation cephalosporins, indicating that this class of antibiotics is no longer suitable for empirical treatment of infections caused by this bacterium. The resistance rate of *KP* strains isolated from patients with HAIs was significantly higher than those isolated from individuals with CAIs. Similar low susceptibility to this class of antibiotics has been reported in previous studies around the world (12, 13, 23, 28).

The study also showed that *KP* strains had very low susceptibility to folate inhibitors (33.7%) and fluoroquinolones (30.3%). This finding aligns with previous studies in Saudi Arabia (26), India (27), and France (23), which demonstrate that these classes of antibacterials are not optimal choices for the initial treatment of *KP* infections in many parts of the world. Resistance to fluoroquinolones in isolates from patients with HAIs (87.0%) was significantly higher than those from patients with CAIs (54.6%).

In the present study, 18% of *KP* isolates were ESBL producers, which was lower than other reports from France (26.8%) and Algeria (88.6%) (23). The reason for this difference is unclear but may be related to different sampling sites or geographic variations in resistant strains. The rate of ESBL production in *KP* strains isolated from patients with HAIs and CAIs was 9.6% and 27.5%, respectively. Fortunately, ESBL-producing strains

demonstrated high susceptibility to carbapenems (92.6%) and moderate sensitivity to aminoglycosides (63.1%), which aligns with findings from other investigations (12).

Overall, the present study showed that all *KP* strains in the study area were susceptible to colistin. Additionally, a significant percentage of strains were susceptible to aminoglycosides and carbapenems. For the initial treatment of severe infections potentially caused by *KP*, using colistin in combination with one or two antibiotics from the aminoglycoside or carbapenem classes appears to be a reasonable approach. We also found that *KP* isolates in the studied patients exhibited high resistance to third- and fourth-generation cephalosporins, folate inhibitors, and fluoroquinolones; therefore, these classes of antibiotics should be considered for use in the de-escalation phase of antibiotic therapy only.

### Acknowledgements

The authors thank B. A. and S. M. for contribution in design and S. N., K. N. and M. B. for assistance in gathering of data in the study. We also thank all physicians, nursing and laboratory staff of the enrolled hospitals and managers of Isfahan Social Security Organization for their help in this investigation.

### Footnotes

**Authors' Contribution:** SNM and SR contributed in concept and design of the study and data acquisition; SR and AA contributed in data collection; SNM, SR, and AA contributed in data analysis and statistical analysis; SNM and AA prepared the manuscript. All authors have substantial work in drafting of the work and final review and approve of the manuscript.

**Conflict of Interests Statement:** All authors have no conflict of interest in regard to any aspect of the study including funding or research support, employment, personal financial interests, consultation fees, and personal or professional relations with organizations and individuals (parents and children, wife and husband, family relationships, etc.) and are not one of the editorial board members or a reviewer of this journal.

**Data Availability:** It has not been declared by the authors.

**Ethical Approval:** This study is approved under the ethical approval code of IR.MUI.MED.REC.1399.233 .

**Funding/Support:** This study was supported in part by grant 399371 from the vice-chancellery for research and technology of Isfahan University of Medical Sciences, Isfahan, Iran and by a teaching and research scholarship from the Isfahan College of Physicians (Dr. Atbin Astaraki) (Webpage of the grant number: <https://researches.mui.ac.ir/banks>).

### References

- Clegg S, Murphy CN. Epidemiology and Virulence of *Klebsiella pneumoniae*. *Microbiol Spectr*. 2016;**4**(1). [PubMed ID: 26999397]. <https://doi.org/10.1128/microbiolspec.UTI-0005-2012>.
- World Health Organization. *Antimicrobial resistance: global report on surveillance*. Geneva, Switzerland: World Health Organization; 2014, [cited 2023]. Available from: [http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748\\_eng.pdf?ua=1](http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1).
- Suwanarat N, Carroll KC. Epidemiology and molecular characterization of multidrug-resistant Gram-negative bacteria in Southeast Asia. *Antimicrob Resist Infect Control*. 2016;**5**:15. [PubMed ID: 27148448]. [PubMed Central ID: PMC4855802]. <https://doi.org/10.1186/s13756-016-0115-6>.
- Chong Y, Shimoda S, Yakushiji H, Ito Y, Miyamoto T, Kamimura T, et al. Community spread of extended-spectrum beta-lactamase-producing *Escherichia coli*, *Klebsiella pneumoniae* and *Proteus mirabilis*: a long-term study in Japan. *J Med Microbiol*. 2013;**62**(Pt 7):1038-43. [PubMed ID: 23538565]. <https://doi.org/10.1099/jmm.0.059279-0>.
- Messaoudi A, Mansour W, Jaidane N, Chaouch C, Boujaafar N, Bouallegue O. Epidemiology of resistance and phenotypic characterization of carbapenem resistance mechanisms in *Klebsiella pneumoniae* isolates at Sahloul University Hospital-Sousse, Tunisia. *Afr Health Sci*. 2019;**19**(2):2008-20. [PubMed ID: 31656484]. [PubMed Central ID: PMC6794520]. <https://doi.org/10.4314/ahs.v19i2.24>.
- Altinkum SM, Ergin S, Bahar H, Torun MM. CTX-M-15 type extended spectrum  $\beta$ -lactamase producing *Escherichia coli* and *Klebsiella pneumoniae*: A developing problem in infected outpatients and hospitalised patients in Istanbul, Turkey. *Afr J Microbiol Res*. 2013;**7**(8):692-7.
- Ghafourian S, Bin Sekawi Z, Sadeghifard N, Mohebi R, Kumari Neela V, Maleki A, et al. The Prevalence of ESBLs Producing *Klebsiella pneumoniae* Isolates in Some Major Hospitals, Iran. *Open Microbiol J*. 2011;**5**:91-5. [PubMed ID: 21915229]. [PubMed Central ID: PMC3170933]. <https://doi.org/10.2174/1874285801105010091>.
- Satlin MJ, Chen L, Patel G, Gomez-Simmonds A, Weston G, Kim AC, et al. Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States. *Antimicrob Agents Chemother*. 2017;**61**(4). [PubMed ID: 28167547]. [PubMed Central ID: PMC5365653]. <https://doi.org/10.1128/AAC.02349-16>.
- Kostyanov T, Vilken T, Lammens C, Timbermont L, Van't Veen A, Goossens H. Detection and prevalence of carbapenem-resistant Gram-negative bacteria among European laboratories in the COMBACTE network: a COMBACTE LAB-Net survey. *Int J Antimicrob Agents*. 2019;**53**(3):268-74. [PubMed ID: 30391381]. <https://doi.org/10.1016/j.ijantimicag.2018.10.013>.
- Li B, Yi Y, Wang Q, Woo PC, Tan L, Jing H, et al. Analysis of drug resistance determinants in *Klebsiella pneumoniae* isolates from a tertiary-care hospital in Beijing, China. *PLoS One*. 2012;**7**(7): e42280. [PubMed ID: 22860106]. [PubMed Central ID: PMC3409176]. <https://doi.org/10.1371/journal.pone.0042280>.

11. Andreu A, Alos JI, Gobernado M, Marco F, de la Rosa M, Garcia-Rodriguez JA, et al. Etiology and antimicrobial susceptibility among uropathogens causing community-acquired lower urinary tract infections: a nationwide surveillance study. *Enferm Infecc Microbiol Clin*. 2005;**23**(1):4-9. [PubMed ID: 15701325]. <https://doi.org/10.1157/13070401>.
12. Mansury D, Motamedifar M, Sarvari J, Shirazi B, Khaledi A. Antibiotic susceptibility pattern and identification of extended spectrum  $\beta$ -lactamases (ESBLs) in clinical isolates of *Klebsiella pneumoniae* from Shiraz, Iran. *Iran J Microbiol*. 2016;**8**(1):55-61. [PubMed ID: 27092225]. [PubMed Central ID: PMC4833741].
13. Hosseinzadeh Z, Sedigh Ebrahim-Saraie H, Sarvari J, Mardaneh J, Dehghani B, Rokni-Hosseini SMH, et al. Emerge of bla(NDM-1) and bla(OXA-48-like) harboring carbapenem-resistant *Klebsiella pneumoniae* isolates from hospitalized patients in southwestern Iran. *J Chin Med Assoc*. 2018;**81**(6):536-40. [PubMed ID: 29030025]. <https://doi.org/10.1016/j.jcma.2017.08.015>.
14. Dallal MM, Khalifeh-Gholi M, Yazdi SS, Mehrani F, Hadayatpour A, Yazdi MK. Antimicrobial resistance pattern of *Klebsiella* spp isolated from patients in Tehran, Iran. *J Surg Med*. 2018;**2**(2). <https://doi.org/10.28982/josam.404979>.
15. Tahanasab Z, Mobasherizadeh S, Moghadampour M, Rezaei A, Maleki N, Faghri J. High prevalence of multiple drug resistance among ESBLs-producing *Klebsiella pneumoniae* isolated from hospitalized patients in Isfahan, Iran. *Med Bacteriol*. 2016;**5**(5-6):29-38.
16. Latifpour M, Gholipour A, Damavandi MS. Prevalence of Extended-Spectrum Beta-Lactamase-Producing *Klebsiella pneumoniae* Isolates in Nosocomial and Community-Acquired Urinary Tract Infections. *Jundishapur J Microbiol*. 2016;**9**(3). e31179. [PubMed ID: 27226874]. [PubMed Central ID: PMC4877671]. <https://doi.org/10.5812/ijmm.31179>.
17. Mostafavi SN, Rostami S, Ataei B, Mobasherizadeh S, Cheraghi A, Haghighipour S, et al. Methodology and Early Results of the First Surveillance Program on Prevention and Control of Antimicrobial Resistance in Isfahan, Iran: The IAS-I Study. *Int J Prev Med*. 2020;**11**:137. [PubMed ID: 33088465]. [PubMed Central ID: PMC7554560]. [https://doi.org/10.4103/ijpvm.IJPVM\\_189\\_19](https://doi.org/10.4103/ijpvm.IJPVM_189_19).
18. Wayne PA. *Performance standards for antimicrobial susceptibility testing*. Pennsylvania, United States: Clinical and laboratory standards institute; 2015-2017, [cited 2023]. Available from: [https://clsi.org/media/3481/m100ed30\\_sample.pdf](https://clsi.org/media/3481/m100ed30_sample.pdf).
19. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect*. 2012;**18**(3):268-81. [PubMed ID: 21793988]. <https://doi.org/10.1111/j.1469-0691.2011.03570.x>.
20. Beyene D, Bitew A, Fantew S, Mihret A, Evans M. Multidrug-resistant profile and prevalence of extended spectrum beta-lactamase and carbapenemase production in fermentative Gram-negative bacilli recovered from patients and specimens referred to National Reference Laboratory, Addis Ababa, Ethiopia. *PLoS One*. 2019;**14**(9). e0222911. [PubMed ID: 31553773]. [PubMed Central ID: PMC6760794]. <https://doi.org/10.1371/journal.pone.0222911>.
21. Del Prete R, Ronga L, Addati G, Magrone R, Abbasciano A, Mosca A, et al. Trends in *Klebsiella pneumoniae* strains isolated from the bloodstream in a teaching hospital in southern Italy. *Le Infezioni Med: rivista Periodica Di Epidemiologia, Epidem, Diagnos, Clin Terapia Delle Patologie Infettive*. 2019;**27**:17-25.
22. Nation RL, Li J. Colistin in the 21st century. *Curr Opin Infect Dis*. 2009;**22**(6):535-43. [PubMed ID: 19797945]. [PubMed Central ID: PMC2869076]. <https://doi.org/10.1097/QCO.0b013e328332e672>.
23. Berrazeg M, Diene SM, Drissi M, Kempf M, Richet H, Landraud L, et al. Biotyping of multidrug-resistant *Klebsiella pneumoniae* clinical isolates from France and Algeria using MALDI-TOF MS. *PLoS One*. 2013;**8**(4). e61428. [PubMed ID: 23620754]. [PubMed Central ID: PMC3631213]. <https://doi.org/10.1371/journal.pone.0061428>.
24. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. *Lancet Infect Dis*. 2010;**10**(9):597-602. [PubMed ID: 20705517]. [PubMed Central ID: PMC2933358]. [https://doi.org/10.1016/S1473-3099\(10\)70143-2](https://doi.org/10.1016/S1473-3099(10)70143-2).
25. Capone A, Giannella M, Fortini D, Giordano A, Meledandri M, Ballardini M, et al. High rate of colistin resistance among patients with carbapenem-resistant *Klebsiella pneumoniae* infection accounts for an excess of mortality. *Clin Microbiol Infect*. 2013;**19**(1):E23-30. [PubMed ID: 23137235]. <https://doi.org/10.1111/1469-0691.12070>.
26. Al-Zalabani A, AlThobyane OA, Alshehri AH, Alrehaili AO, Namankani MO, Aljafri OH. Prevalence of *Klebsiella pneumoniae* Antibiotic Resistance in Medina, Saudi Arabia, 2014-2018. *Cureus*. 2020;**12**(8). e9714. [PubMed ID: 32944436]. [PubMed Central ID: PMC7489314]. <https://doi.org/10.7759/cureus.9714>.
27. Bhaskar BH, Mulki SS, Joshi S, Adhikari R, Venkatesh BM. Colistin Resistance in Carbapenem-Resistant *Klebsiella pneumoniae* Strains. *Asian J Pharmaceutical Clin Res*. 2017;**10**(9):70. <https://doi.org/10.22159/ajpcr.2017.v10i9.18369>.
28. Apondi OE, Oduor OC, Gye BK, Kipkoeh MK. High Prevalence of Multi-Drug Resistant *Klebsiella pneumoniae* in a Tertiary Teaching Hospital in Western Kenya. *Afr J Infect Dis*. 2016;**10**(2):89-95. [PubMed ID: 28480442]. [PubMed Central ID: PMC5411993]. <https://doi.org/10.21010/ajid.v10i2.3>.
29. Veeraraghavan B, Shankar C, Karunasree S, Kumari S, Ravi R, Ralph R. Carbapenem resistant *Klebsiella pneumoniae* isolated from bloodstream infection: Indian experience. *Pathog Glob Health*. 2017;**11**(5):240-6. [PubMed ID: 28670975]. [PubMed Central ID: PMC5560201]. <https://doi.org/10.1080/20477724.2017.1340128>.